Energy Fuels Inc. Acquires RadTran LLC to Enhance Medical Isotope Production Capabilities

Strategic Insights -

Energy Fuels Inc., a leader in uranium and rare earth element production, has acquired RadTran LLC, a company specializing in the separation of critical radioisotopes, to bolster its plans for development and production of medical isotopes used in cancer treatments. The acquisition is expected to significantly enhance Energy Fuels' capabilities to address the global shortage of essential isotopes used in targeted alpha therapies (TAT) for cancer treatment. By combining Energy Fuels' processing capabilities at the White Mesa Mill with RadTran's intellectual property and medical isotope experience, the company aims to position itself as a leader in this developing industry.

Key Takeaways:

  • Energy Fuels has acquired RadTran LLC, a company specializing in the separation of critical radioisotopes, to enhance its medical isotope production capabilities.
  • The acquisition is expected to significantly enhance Energy Fuels' capabilities to address the global shortage of essential isotopes used in TAT for cancer treatment.
  • RadTran's expertise includes the separation of radium-226 and radium-228 from uranium and thorium process streams.
  • Energy Fuels plans to recover valuable isotopes from its existing process streams, recycling back into the market material that would otherwise be lost to disposal, and repurposing it for use in producing life-saving cancer treatments.
  • The company has received regulatory approval and licensing in 2023 for the concentration of R&D quantities of Ra-226 at the Mill and is currently completing engineering on its research and development pilot facility for Ra-226 production.
  • Energy Fuels plans to develop capabilities at the Mill for the commercial-scale production of Ra-226 and potentially Ra-228 in 2026-2028, conditional on completion of engineering design, securing sufficient offtake agreements for final radium production, and receipt of all required regulatory approvals.
  • The demand for Ra-226 and Ra-228 is underscored by the extensive clinical research currently underway, with more than 30 clinical trials evaluating Ac-225, a product of Ra-226 and a crucial component of TAT.
  • Energy Fuels intends to step in to alleviate the supply bottleneck and support development of this important new class of life-saving cancer therapies.

Statistics:

  • Energy Fuels will pay $1.5 million in cash, $1.5 million in Energy Fuels common shares, and a 2% royalty on future revenues from the sale of produced radium, as well as certain other contractual commitments, as part of the Acquisition.
  • The company may pay up to an additional $14 million in cash and common shares based on the satisfaction of performance-based milestones.
  • More than 30 clinical trials are evaluating Ac-225, a product of Ra-226 and a crucial component of TAT, highlighting the urgent need for reliable isotope supply.
  • Several of these trials have reached the final pre-approval stage (phase 3) targeting neuroendocrine tumors and leukemia, with many more earlier stage trials already initiated to address common cancers including prostate cancer.

Sources:

  • Energy Fuels Inc. press release, August 16, 2024
  • Energy Fuels Inc. and RadTran LLC Strategic Alliance Agreement, July 2021
  • White Mesa Mill, Utah, USA
  • RadTran LLC, a private company specializing in the separation of critical radioisotopes